Suppr超能文献

体外膜肺氧合在心源性休克中的应用:年龄对住院死亡率、住院时间和费用的影响。

Extracorporeal Membrane Oxygenation Use in Cardiogenic Shock: Impact of Age on In-Hospital Mortality, Length of Stay, and Costs.

机构信息

Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA.

Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA.

出版信息

Crit Care Med. 2019 Mar;47(3):e214-e221. doi: 10.1097/CCM.0000000000003631.

Abstract

OBJECTIVES

Increasing age is a well-recognized risk factor for in-hospital mortality in patients receiving extracorporeal membrane oxygenation for cardiogenic shock, but the shape of this relationship is unknown. In addition, the impact of age on hospital length of stay, patterns of patient disposition, and costs has been incompletely characterized.

DESIGN

Retrospective analysis of the National Inpatient Sample.

SETTING

U.S. nonfederal hospitals, years 2004-2016.

PATIENTS

Adults with cardiogenic shock treated with extracorporeal membrane oxygenation (3,094; weighted national estimate: 15,415).

INTERVENTIONS

None.

MEASUREMENTS AND MAIN RESULTS

The mean age of extracorporeal membrane oxygenation recipients was 54.8 ± 15.4 years (range, 18-90 yr). Crude in-hospital mortality was 57.7%. Median time-to-death was 8 days (interquartile range, 3-17 d). A linear relationship between age and in-hospital mortality was observed with a 14% increase in the adjusted odds of in-hospital mortality for every 10-year increase in age (adjusted odds ratio, 1.14; 95% CI, 1.08-1.21; p < 0.0001). Thirty-four percent of patients were discharged alive at a median time of 30 days (interquartile range, 19-48 d). The median length of stay and total hospitalization costs were 14 days (interquartile range, [5-29 d]) and $134,573 ($71,782-$239,439), respectively, both of which differed significantly by age group (length of stay range from 17 d [18-49 yr] to 9 d [80-90 yr]; p < 0.0001 and cost range $147,548 [18-49 yr] to $105,350 [80-90 yr]; p < 0.0001).

CONCLUSIONS

Age is linearly associated with increasing in-hospital mortality in individuals receiving extracorporeal membrane oxygenation for cardiogenic shock without evidence of a threshold effect. Median time-to-death is approximately 1 week. One third of patients are discharged from the hospital alive, but the median time-to-discharge is 1 month. Median length of stay ranges from 9 to 17 days depending on age. Hospitalization costs exceed $100,000 in all age groups.

摘要

目的

在接受体外膜肺氧合(ECMO)治疗心源性休克的患者中,年龄的增加是院内死亡率的一个公认的危险因素,但这种关系的形状尚不清楚。此外,年龄对住院时间长短、患者处置模式和成本的影响尚未完全描述。

设计

国家住院患者样本的回顾性分析。

地点

美国非联邦医院,2004 年至 2016 年。

患者

接受 ECMO 治疗的心源性休克成人(3094 例;全国估计值为 15415 例)。

干预措施

无。

测量和主要结果

ECMO 接受者的平均年龄为 54.8±15.4 岁(范围 18-90 岁)。院内死亡率为 57.7%。中位死亡时间为 8 天(四分位距 3-17 d)。观察到年龄与院内死亡率之间呈线性关系,每增加 10 岁,院内死亡率的调整比值比增加 14%(调整比值比,1.14;95%置信区间,1.08-1.21;p<0.0001)。34%的患者在中位时间 30 天(四分位距 19-48 d)时存活出院。中位住院时间和总住院费用分别为 14 天(四分位距 5-29 d)和 134573 美元(71782-239439 美元),这两个参数均按年龄组显著不同(住院时间范围为 17 天[18-49 岁]至 9 天[80-90 岁];p<0.0001,成本范围为 147548 美元[18-49 岁]至 105350 美元[80-90 岁];p<0.0001)。

结论

年龄与接受 ECMO 治疗的心源性休克患者的院内死亡率呈线性相关,无阈值效应的证据。中位死亡时间约为 1 周。三分之一的患者从医院出院,但中位出院时间为 1 个月。住院时间中位数从 9 天到 17 天不等,具体取决于年龄。所有年龄组的住院费用均超过 10 万美元。

相似文献

4
Trends in mortality and resource utilization for extracorporeal membrane oxygenation in the United States: 2008-2014.
Surgery. 2019 Feb;165(2):381-388. doi: 10.1016/j.surg.2018.08.012. Epub 2018 Sep 22.
5
Extracorporeal membrane oxygenation in adults: experience from the Middle East.
Asian Cardiovasc Thorac Ann. 2013 Oct;21(5):521-7. doi: 10.1177/0218492312460858. Epub 2013 Jul 9.
6
Cost-utility of venoarterial extracorporeal membrane oxygenation in cardiogenic shock and cardiac arrest.
Eur Heart J Acute Cardiovasc Care. 2020 Jun;9(4):333-341. doi: 10.1177/2048872619900090. Epub 2020 Jan 31.
7
Venoarterial extracorporeal membrane oxygenation for postcardiotomy shock: Risk factors for mortality.
J Thorac Cardiovasc Surg. 2018 Nov;156(5):1894-1902.e3. doi: 10.1016/j.jtcvs.2018.05.061. Epub 2018 Jun 4.
8
Mortality and costs following extracorporeal membrane oxygenation in critically ill adults: a population-based cohort study.
Intensive Care Med. 2019 Nov;45(11):1580-1589. doi: 10.1007/s00134-019-05766-z. Epub 2019 Sep 16.
10
Rehospitalization and resource use after inpatient admission for extracorporeal life support in the United States.
Surgery. 2019 Nov;166(5):829-834. doi: 10.1016/j.surg.2019.05.013. Epub 2019 Jul 2.

引用本文的文献

3
In Cardiogenic Shock, Age is Not Just a Number.
Card Fail Rev. 2024 Apr 2;10:e04. doi: 10.15420/cfr.2023.22. eCollection 2024.
6
Extracorporeal Membrane Oxygenation for Cardiac Arrest: Does Age Matter?
Crit Care Med. 2024 Jan 1;52(1):20-30. doi: 10.1097/CCM.0000000000006039. Epub 2023 Oct 2.
7
Age-related outcomes in patients with cardiogenic shock stratified by etiology.
J Geriatr Cardiol. 2023 Aug 28;20(8):555-566. doi: 10.26599/1671-5411.2023.08.003.
8
External validation of the REMEMBER score.
Front Cardiovasc Med. 2023 Jul 28;10:1192300. doi: 10.3389/fcvm.2023.1192300. eCollection 2023.
9
Immune function of colon cancer associated miRNA and target genes.
Front Immunol. 2023 Jul 3;14:1203070. doi: 10.3389/fimmu.2023.1203070. eCollection 2023.
10
Trends in Veno-Arterial Extracorporeal Life Support With and Without an Impella or Intra-Aortic Balloon Pump for Cardiogenic Shock.
J Am Heart Assoc. 2022 Dec 6;11(23):e025216. doi: 10.1161/JAHA.121.025216. Epub 2022 Nov 24.

本文引用的文献

1
3
Extracorporeal Circulatory Support in Acute Coronary Syndromes: A Systematic Review and Meta-Analysis.
Crit Care Med. 2017 Nov;45(11):e1173-e1183. doi: 10.1097/CCM.0000000000002692.
7
Extracorporeal Life Support Organization Registry International Report 2016.
ASAIO J. 2017 Jan/Feb;63(1):60-67. doi: 10.1097/MAT.0000000000000475.
8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验